Skip to content

Chonluten

A synthetic tripeptide bioregulator (Glu-Asp-Gly) from the Khavinson system, studied for respiratory and bronchial mucosal health, anti-inflammatory gene regulation, and stress protection in lung tissue.

PreliminaryLimited Data

What is Chonluten?

Chonluten is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and glycine (Glu-Asp-Gly), developed as part of Vladimir Khavinson's bioregulator peptide system at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in bronchial and lung tissue. Its principal biological target is the respiratory system, specifically the bronchial mucosa and lung epithelium. It is often discussed alongside Bronchogen (AEDL), which targets deeper lung tissue and cell differentiation, while Chonluten is more associated with stress-protective and anti-inflammatory gene regulation in respiratory epithelium.

Why People Talk About It

Respiratory and bronchial mucosal health

Preliminary

Anti-inflammatory gene regulation in lung tissue

Preliminary

Adjunct support for chronic bronchitis and COPD

Preliminary

Stress protection under low-oxygen conditions

Limited

Age-related respiratory decline

Limited

How It Works

Chonluten is a tiny three-amino-acid peptide proposed to enter lung and bronchial cells, where it helps regulate genes involved in stress defense and inflammation. It may help the respiratory system manage oxidative stress and inflammatory responses by boosting protective gene programs — particularly those encoding antioxidant enzymes and heat-shock proteins.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Generally well-tolerated in available studiesNo identified side effects in Russian clinical use reports

Cautions

  • Not FDA-approved
  • Clinical data is limited and primarily from Russian research
  • No formal toxicology or pharmacokinetic studies meeting Western regulatory standards
  • No drug interaction studies have been conducted
  • Quality and purity vary by source

What We Don't Know

Western clinical trial data is absent. No dose-escalation studies, formal toxicology, or independent pharmacokinetic data exist. The claimed mechanism of direct DNA interaction by a tripeptide remains debated in the broader scientific community. Long-term safety has not been evaluated in controlled studies.

Published Research

6 studies

Related Peptides

Quick Facts

Class
Bioregulator Peptide
Evidence
Preliminary
Safety
Limited Data
Updated
Apr 2026
Citations
6PubMed

Also known as

EDG PeptideGlu-Asp-GlyT-34Bronchial Bioregulator

Tags

BioregulatorRespiratoryAnti-InflammatoryAnti-AgingKhavinson Peptide

Evidence Score

Overall Confidence18%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.